On Demand CE: Pharmacology Course 2017: The Co-Morbid CVD Patient

Pharmacology Course 2017: The Co-Morbid CVD Patient

Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. PCNA has developed an annual pharmacology CE program to meet the clinical practice and recertification needs of these clinicians.

This year, course director Cindy Lamendola, MSN, NP, and faculty Carol Headley, DNSc., ACNP, RN, CNN and Wei Jiang, MD have developed a curriculum that includes a comprehensive approach to Pharmacology in:
  1. Cardio-Metabolic Risk Reduction in Patients with Pre-Diabetes and DM2 
  2. It’s a Balancing Act: Medication Management in Patients with CKD and CVD
  3. Pharmacological Management of the Cardiac Patient with Depression and/or Anxiety
Those who satisfactorily complete this course will earn 7.0 contact hours in the area of pharmacology. Independent self-paced pre- and post- course evaluation are included. 

Credit: 7.00 Hour Pharmacology CE 
Cost: $45 for members, $115 for non-members

Take this Course

Faculty:

  • Cindy Lamendola MSN, NP, FAHA, FPCNA
  • Carol Headley DNSc., ACNP, RN, CNN
  • Wei Jiang, MD

Upon completion of this activity, participants will be able to: 

  • Understand the role of glucose lowering medications and their relationship with cardiovascular outcomes.
  • Describe the pharmacological treatments used for cardiovascular risk reduction in patients with diabetes and pre-diabetes.
  • Discuss safety and medication adherence when combining common antihypertensive, antilipemic and blood sugar lowering therapies.
  • Review best practices in medication dosing, safety and tolerance in patients with chronic kidney disease and cardiovascular disease.
  • Provide an overview of pharmacotherapies used to prevent the progression of renal dysfunction and reduce cardiovascular risk in patients with chronic kidney disease.
  • Describe how to select and titrate anti-depression and anti-anxiety therapies in patients with cardiovascular disease.
  • Review potential interactions between antidepressant/antianxiety therapies and common cardiovascular medications.

This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is accredited by the American Association of Nurse Practitioners (AANP) as an approved provider of Nurse Practitioner continuing education, provider number 030602.